Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLE-100 as Adjunctive Treatment for Major Depressive Disorder
NCT06340958Phase 2Completed
- Sponsor
- Clexio Biosciences
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CLE-100 in major depressive disorder (MDD), sponsored by Clexio Biosciences. Started Mar 2024; status: completed.
02
Drugs
CLE-100
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06340958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340958.